

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1
-------	---

of

2

Complete if Known

Application Number	10/539.140
---------------------------	-------------------

Filing Date	June 16, 2005
--------------------	----------------------

First Named Inventor	Peter Bernstein
----------------------	-----------------

Art Unit	To Be Determined
----------	------------------

Examiner Name	To Be Determined
---------------	------------------

Attorney Docket Number	ASZN0023-100 (100945-1P US)
------------------------	-----------------------------

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
DO	AA	WO 98/07722	02-26-1998	Pfizer		
	AB	WO 96/39383	12-12-1996	Schering Corp.		
	AC	WO 98/25617	06-18-1998	Merck & Co.		
	AD	EP 0428434	11-06-1990	Sanofi SA		
	AE	EP 0474561	12-09-1998	Sanofi SA		
	AF	EP 0515240	09-24-1997	Sanofi		
	AG	EP 0559538	03-01-1993	Sanofi		

**Examiner
Signature**

Date Considered

9/14/07

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2

of

2

Complete if Known

Application Number	10/539,140
Filing Date	June 16, 2005
First Named Inventor	Peter Bernstein
Art Unit	To Be Determined
Examiner Name	To Be Determined
Attorney Docket Number	ASZN0023-100 (100945-1P US)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AH	Gitlin et al., "Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches," <i>J. Clin. Psych.</i> (1994) 55(9):406-413.	
	AI	Papp et al., "The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats," <i>Behav. Brain Res.</i> (2000) 115(1):19-23.	
	AJ	Ryckmans et al., "First dual NK(1) antagonists-serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants," <i>Bioorg. Med. Chem. Lett.</i> (2002) 12:261-264.	
	AK	Santarelli et al., "Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function," <i>Proc. Nat. Acad. Sci.</i> (2001) 98(4):1912-1917.	
	AL	Schroeder et al., "FLIPR: A New Instrument for Accurate, High Throughput Optical Screening," <i>J. Biomolecular Screening</i> (1996) 1(2):75-80.	
	AM	Stevenson et al., "4,4-Disubstituted piperidine high-affinity NK1 antagonists: structure-activity relationships and in vivo activity," <i>J. Med. Chem.</i> (1998) 41(23):4623-4635.	

Examiner
SignatureDate
Considered

9/14/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.